目的:探讨白菊花抗巨细胞病毒(CMV)诱导的HEL细胞凋亡作用及其可能的分子机制。方法:将HEL细胞分为正常对照组、CMV对照组和药物预处理+CMV作用组,选用三种不同浓度(10μM,20μM and 50μM)的药物预处理三种细胞4h,再以病毒感染各组细...目的:探讨白菊花抗巨细胞病毒(CMV)诱导的HEL细胞凋亡作用及其可能的分子机制。方法:将HEL细胞分为正常对照组、CMV对照组和药物预处理+CMV作用组,选用三种不同浓度(10μM,20μM and 50μM)的药物预处理三种细胞4h,再以病毒感染各组细胞诱导其凋亡,通过MTT法测定各组细胞的存活率,并用流式细胞仪通过Annexin V/PI双染法检测各组细胞的凋亡百分比,用Western blot检测各组细胞中凋亡相关蛋白Caspase-3、6、7、9和NF-κB的表达。结果:不同浓度的白菊花能够提高CMV诱导的HEL细胞的存活率,而且白菊花可降低CMV诱导的HEL细胞的凋亡百分比,其中尤以两种药物的高浓度组作用最为显著,呈现出明显的剂量依赖关系;Western blot检测显示白菊花降低Caspase-3、6、7、9和NF-κB的蛋白表达,且随着浓度的升高,蛋白的表达量表现出逐渐减少的趋势,其中以两种药物的高浓度作用组最为明显。结论:白菊花对CMV诱导的HEL细胞凋亡有不同程度的抑制作用,其机制可能与抑制细胞中凋亡相关蛋白Caspase-3、6、7、9和NF-κB信号传导通路的激活有关。展开更多
目的探究肺结核(pulmonary tuberculosis,PTB)患者血清CXC趋化因子配体8(C-X-C motif chemokine ligand 8,CXCL8)、调节活化正常T细胞表达和分泌因子(regulate upon activation normal T cell expressed and secreted,RANTES)水平与治...目的探究肺结核(pulmonary tuberculosis,PTB)患者血清CXC趋化因子配体8(C-X-C motif chemokine ligand 8,CXCL8)、调节活化正常T细胞表达和分泌因子(regulate upon activation normal T cell expressed and secreted,RANTES)水平与治疗效果的关系。方法选取2020年2月至2021年2月温州医科大学附属衢州医院收治的450例初诊涂阳的PTB患者为研究对象。所有患者均采用标准抗PTB治疗,根据治疗效果分为有效组(n=383)和无效组(n=67)。比较两组一般资料及血清CXCL8、RANTES水平,采用Logistic回归分析PTB患者治疗效果的影响因素以及CXCL8、RANTES对PTB患者治疗效果的预测价值。结果治疗后,450例PTB患者治疗有效率为85.11%。无效组的全程督导占比低于有效组,吸烟、外地户籍占比及治疗前血清CXCL8、RANTES水平高于有效组,差异均有统计学意义(P<0.05),性别、职业、年龄比较,差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,吸烟、户籍类型、CXCL8及管理方式是PTB患者治疗无效的影响因素(P<0.05)。血清CXCL8、RANTES预测PTB患者治疗效果的曲线下面积(areas under the curve,AUC)分别为0.877、0.865,敏感度分别为77.6%、79.1%,特异性分别为88.3%、89.3%;CXCL8、RANTES联合预测PTB患者治疗效果的AUC为0.955,敏感度为94.0%,特异性为85.4%。结论血清CXCL8、RANTES高水平与PTB患者治疗不良密切相关,检测血清CXCL8、RANTES有利于评估PTB患者治疗效果,且二者联合预测效果更佳。展开更多
目的 探讨拉米夫定对乙型肝炎核心抗体(抗-hbc)阳性淋巴瘤患者化疗后病毒激活和肝功能损害的预防作用.方法 79例hbsag(-)而抗-hbc(+)的淋巴瘤患者分为拉米夫定治疗组(37例)和对照组(42例).两组患者均进行联合化疗,期间观察肝功能损害和...目的 探讨拉米夫定对乙型肝炎核心抗体(抗-hbc)阳性淋巴瘤患者化疗后病毒激活和肝功能损害的预防作用.方法 79例hbsag(-)而抗-hbc(+)的淋巴瘤患者分为拉米夫定治疗组(37例)和对照组(42例).两组患者均进行联合化疗,期间观察肝功能损害和hbv激活情况,并用ssps 13.0软件进行统计学分析.结果 预防性应用拉米夫定治疗的37例患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期11例(29.7%),Ⅲ～Ⅳ期2例(5.4%),hbv激活2例(5.4%),而且这2例患者均出现hbv ymdd基因变异.42例化疗时未进行抗病毒治疗的患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期19例(45.2%),Ⅲ～Ⅳ期7例(16.7%),hbv激活12例(28.6%),与拉米夫定治疗组比较差异均具有统计学意义(χ2值分别为79.0、8.7和79.0,p值＜0.05或＜0.01).结论 hbsag(-)而抗-hbc(+)淋巴瘤患者进行化疗时预防性应用拉米夫定可以减少肝脏损害的发生和hbv的激活.
abstract：
objective to evaluate the effectiveness of lamivudine in preventing liver damages and hbv dna reactivation in anti-hbc positive lymphoma patients after chemotherapy.methods seventy-nine lymphoma patients who were negative in hbsag and positive in anti-hbc were enrolled and were divided into lamivudine group (n=37) and control group (n=42).both groups received chemotherapy.liver damages and hbv reactivation were observed, and the data were analyzed with software spss 13.0.results in lamivudine group, liver damages Ⅰ or Ⅱ was observed in 11 patients (11/37, 29.7%), and liver damages Ⅲ or Ⅳ was observed in 2 (2/37, 5.4%); two patients (2/37, 5.4%) developed hbv reactivation, and both of them had hbv ymdd mutations.in control group, 19 (19/42, 45.2%) patients experienced liver damages Ⅰ or Ⅱ, 7 (7/42, 16.7%) experienced liver damages Ⅲ or Ⅳ; 12 (12/42, 28.6%) patients experienced hbv reactivation, the differences between the two groups were of statistical significance (χ2=79.0, 8.7 and 79.0, p ＜ 0.05 or ＜ 0.01).conclusion lamivudine can reduce liver damages and hbv reactivation in hbsag negative and anti-hbc positive patients with lymphoma during chemotherapy.展开更多
文摘目的探究肺结核(pulmonary tuberculosis,PTB)患者血清CXC趋化因子配体8(C-X-C motif chemokine ligand 8,CXCL8)、调节活化正常T细胞表达和分泌因子(regulate upon activation normal T cell expressed and secreted,RANTES)水平与治疗效果的关系。方法选取2020年2月至2021年2月温州医科大学附属衢州医院收治的450例初诊涂阳的PTB患者为研究对象。所有患者均采用标准抗PTB治疗,根据治疗效果分为有效组(n=383)和无效组(n=67)。比较两组一般资料及血清CXCL8、RANTES水平,采用Logistic回归分析PTB患者治疗效果的影响因素以及CXCL8、RANTES对PTB患者治疗效果的预测价值。结果治疗后,450例PTB患者治疗有效率为85.11%。无效组的全程督导占比低于有效组,吸烟、外地户籍占比及治疗前血清CXCL8、RANTES水平高于有效组,差异均有统计学意义(P<0.05),性别、职业、年龄比较,差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,吸烟、户籍类型、CXCL8及管理方式是PTB患者治疗无效的影响因素(P<0.05)。血清CXCL8、RANTES预测PTB患者治疗效果的曲线下面积(areas under the curve,AUC)分别为0.877、0.865,敏感度分别为77.6%、79.1%,特异性分别为88.3%、89.3%;CXCL8、RANTES联合预测PTB患者治疗效果的AUC为0.955,敏感度为94.0%,特异性为85.4%。结论血清CXCL8、RANTES高水平与PTB患者治疗不良密切相关,检测血清CXCL8、RANTES有利于评估PTB患者治疗效果,且二者联合预测效果更佳。
文摘目的 探讨拉米夫定对乙型肝炎核心抗体(抗-hbc)阳性淋巴瘤患者化疗后病毒激活和肝功能损害的预防作用.方法 79例hbsag(-)而抗-hbc(+)的淋巴瘤患者分为拉米夫定治疗组(37例)和对照组(42例).两组患者均进行联合化疗,期间观察肝功能损害和hbv激活情况,并用ssps 13.0软件进行统计学分析.结果 预防性应用拉米夫定治疗的37例患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期11例(29.7%),Ⅲ～Ⅳ期2例(5.4%),hbv激活2例(5.4%),而且这2例患者均出现hbv ymdd基因变异.42例化疗时未进行抗病毒治疗的患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期19例(45.2%),Ⅲ～Ⅳ期7例(16.7%),hbv激活12例(28.6%),与拉米夫定治疗组比较差异均具有统计学意义(χ2值分别为79.0、8.7和79.0,p值＜0.05或＜0.01).结论 hbsag(-)而抗-hbc(+)淋巴瘤患者进行化疗时预防性应用拉米夫定可以减少肝脏损害的发生和hbv的激活.
abstract：
objective to evaluate the effectiveness of lamivudine in preventing liver damages and hbv dna reactivation in anti-hbc positive lymphoma patients after chemotherapy.methods seventy-nine lymphoma patients who were negative in hbsag and positive in anti-hbc were enrolled and were divided into lamivudine group (n=37) and control group (n=42).both groups received chemotherapy.liver damages and hbv reactivation were observed, and the data were analyzed with software spss 13.0.results in lamivudine group, liver damages Ⅰ or Ⅱ was observed in 11 patients (11/37, 29.7%), and liver damages Ⅲ or Ⅳ was observed in 2 (2/37, 5.4%); two patients (2/37, 5.4%) developed hbv reactivation, and both of them had hbv ymdd mutations.in control group, 19 (19/42, 45.2%) patients experienced liver damages Ⅰ or Ⅱ, 7 (7/42, 16.7%) experienced liver damages Ⅲ or Ⅳ; 12 (12/42, 28.6%) patients experienced hbv reactivation, the differences between the two groups were of statistical significance (χ2=79.0, 8.7 and 79.0, p ＜ 0.05 or ＜ 0.01).conclusion lamivudine can reduce liver damages and hbv reactivation in hbsag negative and anti-hbc positive patients with lymphoma during chemotherapy.
